GlassScriptPhysician profile
Rickey L Snipes
NPI 1477546869
$2,230.49
in general payments reported to CMS, 2019-2025
30 companies · $202 in 2025
The $202 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $113 · 2021: $222 · 2022: $630 · 2023: $329 · 2024: $409 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $896 · Education: $43.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $896.31 |
| Education | $43.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $409.64 | 2019-2025 | Rinvoq, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $249.70 | 2019-2025 | Eohilia, Gattex, Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.76 | 2019-2024 | Xifaxan, Trulance |
| Intercept Pharmaceuticals, INC. | $135.97 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $134.24 | 2022 | |
| Boston Scientific Corporation | $129.76 | 2022 | |
| Pfizer INC. | $128.34 | 2019-2025 | |
| Gilead Sciences, INC. | $119.87 | 2019-2025 | |
| Janssen Biotech, INC. | $106.87 | 2020-2024 | Stelara, Simponi, Simponi Aria |
| Genzyme Corporation | $82.94 | 2022 | |
| Nestle Healthcare Nutrition INC. | $76.74 | 2022 | |
| Merck Sharp & Dohme LLC | $65.07 | 2019-2024 | Dificid, Zerbaxa |
| Lilly USA, LLC | $54.43 | 2024-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $48.13 | 2019-2024 | Rebyota |
| Alexion Pharmaceuticals, INC. | $34.00 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $33.14 | 2021 | |
| Daiichi Sankyo INC. | $33.04 | 2019-2024 | Injectafer |
| Aimmune Therapeutics, INC. | $26.51 | 2025 | Zenpep |
| Ardelyx, INC. | $25.14 | 2023 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.77 | 2023 | Cyltezo |
| Ipsen Biopharmaceuticals, INC | $22.94 | 2024 | Iqirvo |
| Madrigal Pharmaceuticals | $22.19 | 2025 | Rezdiffra |
| Celgene Corporation | $19.60 | 2024 | Zeposia |
| Novo Nordisk INC | $19.21 | 2025 | Wegovy |
| Shionogi INC | $19.08 | 2019 | |
| Fresenius Kabi USA, LLC | $15.85 | 2023 | Idacio |
| Shield Therapeutics INC | $13.63 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $13.44 | 2023 | Dupixent |
| Ucb, INC. | $11.55 | 2019 | |
| Ironwood Pharmaceuticals, INC | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rickey Snipes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.